Aurinia Pharma Acquires Kezar Life Sciences for $51M

Aurinia Pharma U.S., Inc. has completed its acquisition of Kezar Life Sciences, Inc. for approximately $51 million. This deal involved a purchase price of $6.955 per share in cash along with a contingent value right (CVR) per share. This transaction underscores Aurinia’s strategic move to expand its portfolio by integrating Kezar's capabilities with its own.

The tender offer process concluded on May 8, 2026, with the merger finalizing on May 11, 2026. Aurinia secured more than 80% of the outstanding shares of Kezar, meeting the Minimum Tender Condition and thereby facilitating a swift closure of the deal. Kezar will continue to operate as a wholly owned subsidiary of Aurinia. Each outstanding share was converted into the designated cash consideration plus CVR, following the merger agreement.

The acquisition was executed under Section 251(h) of the Delaware General Corporation Law, which permits mergers without a stockholder vote when conditions are met. Consequently, eligible shareholders maintain their appraisal rights, allowing them to contest the share valuation if they choose. The absorbed shares ceased trading prior to the market opening on May 11, 2026, with plans underway to delist and deregister Kezar from the Exchange Act.

For Aurinia, this acquisition is strategically significant as it potentially benefits from Kezar's research and development programs, aiming to complement and enhance its own pipeline in pharmaceutical products. The merger aligns with Aurinia’s goal to fortify its market position and expand its therapeutic offerings.

The closure of this deal emphasizes the consolidation trend in the biotechnology and pharmaceutical sectors. Competing firms might observe these dynamics closely as M&A activities continue to shape the competitive landscape. The emphasis on integrating research capabilities could prompt similar moves among other sector players to remain competitive.

Going forward, the procedural steps for delisting and the resolution of any appraisal claims will be keenly observed. These actions will determine how efficiently Aurinia can integrate Kezar operations and navigate regulatory obligations following the merger.